What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.